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Abstract 16 
New psychoactive substances (NPS) are a new breed of synthetically produced 17 
substances designed to mimic the effects of traditional illegal drugs. Synthetic 18 
cannabinoids and synthetic cathinones are the two most common groups, which try to 19 
mimic the effects of the natural compounds 
9Δ-tetrahydrocannabinol and cathinone, 20 
respectively. Similarly, synthetic tryptamines are designer compounds which are based 21 
on the compounds psilocin, N,N-dimethyltryptamine and 5-methoxy-N,N-22 
dimethyltryptamine found in some mushrooms. One of the most important tryptamine 23 
compounds found in seizures is 5-methoxy-N,N-diisopropyltryptamine, which has been 24 
placed as controlled substance in USA and some European countries. The control of this 25 
compound has promoted the rising of another tryptamine, the 5-methoxy-N-methyl-N-26 
isopropyltryptamine , which at the time of writing this article has not been banned yet. 27 
So, it is undeniable that this new substance should be monitored. 28 
5-methoxy-N-methyl-N-isopropyltryptamine has been reported by the Spanish Early 29 
Warning System and detected in our laboratory in two pill samples purchased in a local 30 
smart shop. This has promoted the need of stablishing consumption markers for this 31 
compound in consumers’ urine. In the present work, the metabolism and 32 
pharmacokinetic of 5-methoxy-N-methyl-N-isopropyltryptamine has been studied by an 33 
in vivo approach, using adult male mice of the inbred strain C57BLJ/6. The use of ultra-34 
high performance liquid chromatography coupled to high resolution mass spectrometry 35 
allowed the identification of four metabolites. After the pharmacokinetic study in serum 36 
and urine, the O-demethylated metabolite and the non-metabolised parent compound are 37 
proposed as consumption markers in hydrolysed urine.. Data reported in this work will 38 
help hospitals and forensic laboratories to monitor the consumption and potential 39 
intoxication cases related to this tryptamine. 40 
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1. Introduction 45 
The term “new psychoactive substances” (NPS) includes synthetic compounds, but also 46 
plant or fungal substances that are used as recreational drugs by elicitation of a 47 
psychoactive response, and that are not classified as illegal substances [1]. Synthetic 48 
cannabinoids and synthetic cathinones make up most of the NPS described for the 49 
EMCDDA in its 2016 report [2]. These compounds try to produce the same 50 
psychoactive effects than 
9Δ-tetrahydrocannabinol (THC), a natural compound found in 51 
cannabis (Cannabis sativa), or the natural alkaloid cathinone found in khat (Catha 52 
edulis) [3], respectively. Other widely consumed natural products are the “magic 53 
mushrooms” belonging to the genera Psilocybe, Conocybe and Hygrocybe [1]. These 54 
fungi, especially Psilocybe cubensis, contain high concentrations of psilocybin (4-55 
phosphoryloxy-N,N-dimethyltryptamine) and psilocin (4-hydroxy-N,N-56 
dimethyltriptamine), natural tryptamines with hallucinogenic and sedative effects [4]. 57 
Other natural tryptamines currently consumed are DMT (N,N-dimethyltryptamine) and 58 
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), both of them present in the popular 59 
“ayahuasca” [4,5]. Several new tryptamines, structurally similar to natural ones, have 60 
been detected in the last few years. One of the most popular synthetic tryptamine is 5-61 
MeO-DiPT (5-methoxy-N,N-diisopropyltryptamine), and its analogues DiPT (N,N-62 
diisopropyltryptamine) and 4-OH-DiPT (4-hydroxy-N,N-diisopropyltryptamine).  63 
The compound 5-MeO-DiPT (also known as “Foxy” or “Foxy Methoxy”) was reported 64 
for the first time in 1999, and in 2003 the DEA reported law enforcements seizures for 65 
this compound [6]. Some studies revealed that this tryptamine is a high affinity inhibitor 66 
of serotonin, dopamine and norepinephrine transporters [7], but it also acts as a toxin of 67 
the serotonergic cells in the brain [8–11]. After the inclusion of 5-MeO-DiPT and its 68 
natural analogue 5-MeO-DMT in the list of controlled substances in USA and some 69 
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European countries [12,13], another tryptamine has been recently identified, 5-MeO-70 
MiPT (5-methoxy-N-methyl-N-isopropyltryptamine), which is a 5-MeO-DMT 71 
derivative that changes a N-methyl group by N-isopropyl. This compound, as well as its 72 
derivatives MiPT and 4-OH-MiPT, were already described by Alexander Shulgin in his 73 
book [14]. Figure 1 shows the structure of natural tryptamines and their synthetic 74 
analogues, including 5-MeO-DiPT and 5-MeO-MiPT. The last one has been reported in 75 
intoxication episodes [15,16]. In Spain, it was reported by the Early Warning System 76 
(EWS) in 2016, with its first detection taking place in April 2015 [17]. 77 
It seems evident that 5-MeO-MiPT should be monitored in seizures and possible 78 
intoxication cases. Identification of NPS is commonly an analytical challenge because 79 
NPS structures are continuously changing, needing complex and complementary 80 
techniques for their structural elucidation [18,19]. In addition, the detection of these 81 
compounds in biological samples with the aim of determining the origin of an 82 
intoxication/consumption is troublesome. The main handicap lies on the establishment 83 
of the target compound to be monitored, which in many cases is unknown to the analyst. 84 
Several works developing methodologies for the determination of NPS in blood and 85 
urine have been published, searching for the parent compound [21–24]. However, prior 86 
to monitoring NPS in biological fluids, drug metabolism studies are commonly 87 
required. These studies allow to identify the major metabolites and the most specific 88 
ones, thus establishing the potential consumption biomarkers. 89 
Undoubtedly, the most useful experiments would be with humans, but these are in most 90 
cases rather problematic, as they are limited to intoxication cases [25] and/or require the 91 
participation of healthy volunteers [26], with the subsequent risk. At this point, in vitro 92 
experiments, using microsomes or cell cultures, and in vivo experiments, using animal 93 
models, are the most common way of establishing potential consumption markers. The 94 
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in vivo approach has been successfully used in different NPS metabolite identification 95 
studies [27–31]. For the tryptamine derivative 5-MeO-DiPT, its metabolites have been 96 
studied using the in vitro approach with rat liver microsomes [32] and rat and human 97 
hepatocytes [33], as well as using in vivo experiments with urine of rats [34] and human 98 
volunteers [35]. These experiments have allowed monitoring the consumption of this 99 
substance throughout the analysis of biological samples, searching for the markers 100 
previously established [36].  101 
Our research started when the 5-MeO-MiPT was identified in two pill samples 102 
purchased in a local smart shop, at the same time than the Spanish EWS reported its 103 
presence, which encourage us to study its metabolism (no data was found in literature). 104 
In vivo experiments were carried out with adult male mice of the inbred strain 105 
C57BLJ/6. Ultra-high performance liquid chromatography coupled to high resolution 106 
mass spectrometry (UHPLC-HRMS) was used for metabolite structural elucidation. 107 
Using different approaches for metabolite identification, two Phase I and two Phase II 108 
metabolites were tentatively identified. The identified Phase I metabolites resulted from 109 
demethylation of the methoxy group and the putative formation of the N-oxide, while 110 
the Phase II were the glucuronide conjugation of the demethylated metabolite, and the 111 
glucuronide of the hydroxyindole metabolite.  112 
  113 
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2. Experimental procedures 114 
2.1. Reagents and chemicals  115 
5-MeO-MiPT reference standard was purchased from Cayman Chemical (Ann Arbor, 116 
MI, USA). HPLC-grade water was obtained by purifying demineralised water using a 117 
Milli-Q system from Millipore (Bedford, MA, USA). HPLC-grade methanol (MeOH), 118 
HPLC-grade acetonitrile (ACN), acetone, sodium chloride (NaCl), dimethyl sulfoxide 119 
(DMSO), formic acid (HCOOH), hydrochloric acid (HCl 37%) and sodium hydroxide 120 
(NaOH) were purchased from Scharlau (Scharlab, Barcelona, Spain). Diamino 121 
hydrogen phosphate ((NH4)2HPO4) was purchased from Merck (Darmstadt, Germany). 122 
β-glucuronidase from E. Coli K12 (80 U/mg at 25 ºC) was purchased from Roche 123 
(Indianapolis, IN, USA). Leucine enkephalin was acquired from Sigma-Aldrich (St. 124 
Louis, MO, USA). 125 
1 M H2PO4
-
/HPO4
-2
 buffer was prepared by dissolving the corresponding amount of 126 
(NH4)2HPO4 in Milli-Q water and adjusting the pH to 7 with HCl. 127 
 128 
2.2. Legal high samples containing 5-MeO-MiPT 129 
Two different pills, Estrella (which means “Star” in Spanish) and Corazon (“Heart”) 130 
(Figure 2) were bought in a local smart shop through its webpage. Both samples were 131 
analysed in order to identify the NPS present in their composition. The tryptamine 5-132 
MeO-MiPT was tentatively identified in both samples and unequivocally identified after 133 
purchasing its reference standard. 134 
 135 
2.3. Animal experiments 136 
In vivo experiments were performed using C57BLJ6 adult male mice (Janvier, France). 137 
The study protocol was approved by the ethical committee of Generalitat Valenciana 138 
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(Ref. 2015/VSC/PEAI00055). Animals were caged in groups of 3-4 mice and they 139 
received intra-peritoneal (i.p.) injections of the drug solution or the vehicle (control). 140 
Different groups of animals were used to obtain blood and urine samples. 141 
150 µL of blank solution (0.9% of NaCl and 1% of DMSO) were injected to control 142 
group, while for metabolism experiments, 5-MeO-MiPT was added to blank solution in 143 
order to obtain a dose of 0.27 mg/kg in a 150 µL injection. This dose was estimated 144 
based on a rough quantification of the 5-MeO-MiPT in pill samples by area comparison 145 
with the 5-MeO-MiPT standard, considering a standard human consumer of 75 kg. 146 
For obtaining blood samples, four groups of three animals were injected with the 5-147 
MeO-MiPT solution. Ten, 20, 40 and 60 min after drug administration, animals were 148 
quickly sacrificed by cervical dislocation and decapitated to obtain large volumes of 149 
blood. For the control group (three animals), blood was collected in the same way, 60 150 
min after vehicle injections. Blood of each animal was allowed to coagulate and 151 
centrifuged. The serum from the animals of each group (either experimental or control) 152 
was mixed, and aliquots were frozen for subsequent use. In conclusion, a total of five 153 
serum samples (3 animals per sample) was obtained, one control and four obtained at 154 
different times after 5-MeO-MiPT administration.  155 
For urine samples, four groups of three animals were injected with 5-MeO-MiPT 156 
solution, and four groups of three animals with the blank solution. Urine from control 157 
and 5-MeO-MiPT groups were collected at 1, 2, 3, 4, 5, 6 and 24 h after the 158 
administration of the drug or the vehicle solution. To do so, the three mice were put 159 
together in a previously sterilized, regular home cage with a meshwire platform that 160 
allowed safely collecting urine and avoiding those areas were excrements were present. 161 
The sample obtained at a given time point after drug or vehicle injection, was 162 
centrifuged, and the aliquots of the urine were frozen for its subsequent use. In 163 
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summary, seven control samples and seven 5-MeO-MiPT samples, obtained at different 164 
times after vehicle/drug administration (respectively), were collected.  165 
 166 
2.4. Sample treatment 167 
For the pill samples, the same extraction procedure described in literature for extracting 168 
NPS from legal highs samples was used [18]. Approximately 50 mg of sample was 169 
weighted in 2 mL propylene tubes and 1 mL of acetone was added. Extraction was 170 
performed under sonication during 15 min. After centrifugation during 15 min at 12000 171 
rpm, supernatant was 10
4
-fold diluted with H2O:MeOH 90:10 and injected into the 172 
UHPLC-HRMS system. 173 
For the blood samples, 300 µL of ACN were added to 100 µL of serum in 2 mL 174 
propylene tubes. Extracts were shaken during 1 min in a vortex in order to insolubilize 175 
the proteins and centrifuged at 12000 rpm during 10 min. Supernatant was collected and 176 
evaporated until dryness under gentle nitrogen stream at 40 ºC. Solid residue was 177 
dissolved with 100 µL H2O:MeOH (90:10) and 20 µL were injected into the UHPLC-178 
HRMS. 179 
For urine samples, two different procedures were used in order to evaluate Phase I and 180 
Phase II metabolites. For Phase I studies, the procedure used was adapted from the 181 
literature [35–37]. Briefly, 200 µL of mice urine were hydrolysed with of 10 µL of β-182 
glucuronidase, buffering the sample with 100 µL of a phosphate buffer adjusted to pH = 183 
7. After incubating for 1 hour at 55 ±2 ºC, samples were frozen for 3 hours in order to 184 
remove proteins and lipids by precipitation. Finally, samples were centrifuged at 12000 185 
rpm during 15 min and 20 µL of supernatant were injected into the UHPLC-HRMS 186 
system. For Phase II metabolites identification, 100 µL of mice urine was diluted with 187 
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100 µL Milli-Q water and frozen in order to remove lipids and proteins. After that, 188 
sample was centrifuged at 12000 rpm during 15 min and 20 µL were injected. 189 
 190 
2.5. Instrumentation 191 
Sample analysis were performed using an Acquity UPLC liquid chromatography system 192 
(Waters, Mildford, MA, USA) interfaced to a XEVO G2 QTOF hybrid quadrupole-time 193 
of flight (QTOF) mass spectrometer (Waters Micromass, Manchester, UK) with an 194 
orthogonal Z-spray electrospray (ESI) operating in positive and negative ionisation 195 
mode. A CORTECS C18 100 x 2.1 mm 2.7 µm particle size analytical column (Waters) 196 
was used to perform chromatographic separation, with a flow rate of 0.3 mL/min. 197 
Mobile phases were H2O with 0.01% HCOOH (A) and MeOH with 0.01% HCOOH 198 
(B). The mobile phase gradient was performed as follows: 10% of B at 0 min, 90% of B 199 
at 14 min linearly increased, 90% of B at 16 min, and finally 10% B at 18 min in order 200 
to return to initial conditions. The injection volume was 5 µL for MS
E
 acquisition, and 201 
20 µL for MS/MS experiments. The column temperature was set to 40ºC. The TOF 202 
resolution was ~20000 at FWHM at m/z 556 in positive ionisation mode. The range 203 
acquired by the MS system was from m/z 50 to 1000. A capillary voltage of 0.7 kV and 204 
a cone voltage of 20 V for positive ionisation, and a capillary voltage of -1.5 kV and a 205 
cone voltage of 20 V for negative ionisation were used during all the chromatographic 206 
run. Nitrogen (Praxair, Valencia, Spain) was used as desolvation and nebulizing gas. 207 
The desolvation gas flow was set at 1000 L/h. Argon 99.995% (Praxair) was used as a 208 
collision gas. The interface temperature was set to 600ºC and the source temperature to 209 
120ºC. For MS
E
 experiments, two acquisition functions with different collision energy 210 
were created. The low energy function (LE) used a collision energy of 4 eV in order to 211 
obtain information about the (de)protonated molecule and adducts (if exist), while the 212 
11 
 
high energy function (HE) applied a collision energy ramp from 15 to 40 eV, in order to 213 
promote collision-induced fragmentation of the compounds. Calibration of the mass-214 
axis was performed daily from m/z 50 to 1000 using a 1:1 mixture of 0.05M NaOH:5% 215 
HCOOH, diluted 1:25 with ACN:H2O 80:20 mixture. For accurate mass measurement, 216 
a 2 µg/mL leucine enkephalin solution in ACN:H2O 50:50 with 0.1% HCOOH was 217 
used as lock-mass, pumped at a flow rate of 20 µL/min. The leucine enkephalin 218 
(de)protonated molecule (m/z 556.2771 for positive ionisation, and m/z 554.2515 for 219 
negative) were used for recalibrating the mass axis and ensure an accurate mass during 220 
all the chromatographic run. MS data were acquired in continuum mode using 221 
MassLynx data station operation software version 4.1 (Waters), and processed with 222 
UNIFI scientific information system version 1.8 (Waters). 223 
 224 
 225 
  226 
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3. Results and discussion 227 
3.1. Identification of 5-MeO-MiPT in legal highs samples 228 
The suspect screening of the legal highs samples (Estrella and Corazon) retrieved the 5-229 
MeO-MiPT as a potential candidate to be present in both pills. After an accurate 230 
fragment evaluation, the compound was tentatively identified in the two samples. 231 
Figure 3A shows the LE and HE spectra (Left) of the chromatographic peak at 3.24 232 
min observed after analysis of Estrella pill. The extracted ion chromatograms (EIC) of 233 
the protonated molecule and the collision induced dissociation (CID) fragments are also 234 
showed (Right). The tentative identification of the compound was based on the 235 
fragmentation observed. After this careful evaluation, the analytical reference standard 236 
of 5-MeO-MiPT was bought to unequivocally confirm the identity of the compound 237 
based on retention time and fragmentation (Figure 3B). 238 
 239 
3.2. Mass spectrometric behaviour of 5-MeO-MiPT 240 
Initially, an accurate study of the CID fragments of the parent compound was performed 241 
in order to understand the differences on the fragmentation pathways of the potential 242 
metabolites respect the parent compound. 5-MeO-MiPT was observed only in positive 243 
ionisation mode (m/z 247.1810) as protonated molecule ([M+H]
+
) due to the presence of  244 
amine moieties.  245 
The fragmentation spectrum showed five fragment ions (Figure 3A). The most intense 246 
fragment ion was observed at m/z 174.0916 (C11H12NO
+
), corresponding to the neutral 247 
loss of the N-isopropylmethylamine (73.0892 Da). The second most intense fragment, at 248 
m/z 86.0972 (C5H12N
+
), corresponded to the N-isopropylmethylamine with an additional 249 
N-methylene coming from the alkyl chain bonded to the amine with the indole ring. 250 
This fragment has its complementary ion fragment corresponding to the molecule 251 
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without the functionalised amine at m/z 159.0683 (C10H9NO
+·
). In this case, the 252 
fragment corresponded to a radical ion originated by a homolytic cleavage. This 253 
fragment is the precursor ion of another radical fragment at m/z 131.0732 (C9H9N
+·
), 254 
originated by a 27.9949 Da neutral loss (corresponding to a CO molecule). Finally, 255 
fragment at m/z 143.0733 (C10H9N
+·
) would come from fragment ion at m/z 174 after a 256 
methoxide radical loss (CH3O
·
). It can be observed than fragments involving radicals 257 
are quite less intense that full-paired electron fragments. The complete fragmentation 258 
pathway of 5-MeO-MiPT can be found in Supplementary Information (SI.1). 259 
The accurate fragmentation study revealed that the protonation centre would be the N-260 
isopropylmethylamine instead of the indole ring, as the fragmentation of the molecule 261 
starts on the functionalised amine. 262 
 263 
3.3. Analytical strategy for detecting 5-MeO-MiPT metabolites in mice serum and urine 264 
The detection of 5-MeO-MiPT metabolites was performed by 3 different approaches, 265 
using UNIFI scientific information system for data processing and compound 266 
elucidation. The first approach consisted on the comparison between the blood and 267 
urine samples collected after injection with 5-MeO-MiPT, and the control samples, 268 
obtained from mice injected with blank solution. Only the compounds which were 269 
present in 5-MeO-MiPT samples in a 5:1 ratio with respect to blank samples were 270 
considered as potential metabolites. This ratio was experimentally stablished in order to 271 
avoid false-positives (endogenic compounds that could be proposed as potential 272 
metabolites) or false-negatives (no detection of a potential metabolite due to its 273 
confusion with an endogenic compound present in blanks). For urine samples, each 5-274 
MeO-MiPT sample had its corresponding control sample collected at the same time. In 275 
the case of blood samples, blank sample collected at 60 min was used as reference for 276 
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compound discrimination in all blood samples. Obviously, control samples were 277 
processed with the same sample treatment than drug samples. Once identified the 278 
potential metabolites, metabolite structure was determined based on the observed 279 
fragmentation. 280 
In the second approach, 5-MeO-MiPT metabolites were searched based on expected 281 
biotransformations in a two-step strategy for urine samples. The first step was to search 282 
for Phase I metabolites in the hydrolysed urine. In this step, potential Phase I 283 
metabolites were searched by applying Phase I biotransformations (such as cleavages, 284 
oxidations, reductions…) to the elemental composition of 5-MeO-MiPT. Once 285 
identified all the Phase I metabolites, Phase II metabolites were searched in the diluted 286 
non-hydrolysed urine. Now, conjugations with glucuronides or sulphates of the 287 
elemental composition of the parent compound and the elucidated Phase I metabolites 288 
were searched.  289 
Finally, in the third approach, the common fragmentation pathway and neutral loss 290 
search strategies were applied, assuming that some metabolites would share common 291 
fragments and/or neutral losses with the parent compound. 292 
In the case of serum, due to the low amount obtained, the hydrolysis step could not be 293 
performed.  294 
The combination of the three different approaches allowed the identification of two 295 
Phase I and two Phase II metabolites. The four identified metabolites were detected only 296 
in positive ionisation mode. In negative ionisation mode, no additional metabolites were 297 
identified.  298 
 299 
3.4. 5-MeO-MiPT Phase I metabolites 300 
Demethylated metabolite (Metabolite 1) 301 
15 
 
The Metabolite 1 was detected at m/z 233.1649 ([M+H]
+
, C14H21N2O
+
, at 302 
chromatographic retention time (rt) of 2.49 min), which was the result of the loss of a 303 
methyl group respect the 5-MeO-MiPT. The fragments observed (Figure 4A, Table 1) 304 
were similar to the observed for 5-MeO-MiPT. The fragments at m/z 86.0961 (C5H12N
+
) 305 
and m/z 160.0751 (C10H10NO
+
), and the corresponding neutral loss of the N-306 
isopropylmethylamine (73.0892 Da), were also observed for the 5-MeO-MiPT. This 307 
fragmentation would suggest that the demethylation point was not located in the 308 
functionalised amine but in the methoxy group. Additionally, the fragment at m/z 309 
142.0648 (C10H8N
+
) was also observed for the 5-MeO-MiPT, with a difference of 1 Da. 310 
This fragment ion was obtained after the homolytic fragmentation of a methoxy loss 311 
instead of the heterolytic fragmentation of a water loss observed for the parent 312 
compound. Fragment at m/z 132.0799 (C9H10N
+
) has also the same 1 Da difference 313 
respect to the corresponding 5-MeO-MiPT fragment, produced by heterolytic/homolytic 314 
fragmentation. The other two minor fragments at m/z 117.0573 (C8H7N
+·
) and m/z 315 
115.0536 (C9H7
+·
) were not observed for 5-MeO-MiPT. 316 
After this accurate fragmentation analysis, a plausible fragmentation pathway for the 317 
Metabolite 1 was proposed (Figure 4B). The aromaticity of the indole ring, and the 318 
multiple resonance structures that could be formed allow the fragmentation of the 319 
molecule by the groups linked to the indole ring even though the protonation only occur 320 
in the amine moiety. 321 
 322 
N-oxide metabolite (Metabolite 2) 323 
Metabolite 2 presented its [M+H]
+
 at m/z 263.17531 (C15H23N2O2
+
, rt 4.30 min), 324 
corresponding to a hydroxylation. This compound presented four fragment ions at m/z 325 
174.0913 (C11H12NO
+
), m/z 159.0685 (C10H9NO
+·
), m/z 143.0731 (C10H9N
+·
) and m/z 326 
16 
 
131.0723 (C9H9N
+·
) (Table 1), all of them shared with the 5-MeO-MiPT. These 327 
fragments would suggest the hydroxylation to occur in the amine group. This is in 328 
accordance with the neutral loss of 89.0841 Da observed (263174), which 329 
corresponds to an elemental composition of C4H11NO. According to literature, the 330 
hydroxylation in an alkylic chain would produce the loss of a water molecule during 331 
CID fragmentation [38]. However, this fragment was not observed, indicating that the 332 
hydroxylation point would be the nitrogen atom. The formation of N-oxides in 333 
tryptamine analogues has been described in literature [28,39]. On this way, the putative 334 
structure of Metabolite 2 would be the N-oxide of 5-MeO-MiPT. MS
E
 fragmentation 335 
spectrum of Metabolite 2 and the proposed fragmentation pathway for its structure can 336 
be found in Supplementary Information SI.2. 337 
 338 
3.5. 5-MeO-MiPT Phase II metabolites 339 
Glucuronide conjugation of Metabolite 1 (Metabolite 3) 340 
Once identified the two Phase I metabolites, Phase II metabolites were investigated. A 341 
drug-unique peak in raw urine and serum samples was detected, fitting with the 342 
glucuronide conjugate of Metabolite 1 (m/z 409.1965, C20H29N2O7
+
, rt 1.30 min). The 343 
position of the glucuronide conjugation was determined based on the observed 344 
fragmentation (Table 1). The “key” fragment was observed at m/z 336.1061 345 
(C16H18NO7
+
), corresponding to the neutral loss of N-isopropylmethylamine (73.0892 346 
Da), also present for 5-MeO-MiPT and Metabolite 1. This fragment indicates that the 347 
glucuronide conjugation should have occurred in the hydroxyl group of the indole ring, 348 
discarding the formation of an N-glucuronide. Therefore, this compound would 349 
correspond to the glucuronide of Metabolite 1. The fragment present at m/z 233.1637 350 
involved the loss of the glucuronide, releasing the non-conjugated part (C14H21N2O
+
). 351 
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The other two observed fragments at m/z 160.0750 (C10H10NO
+
) and m/z 86.0963 352 
(C5H12N
+
) were shared with Metabolite 1, as expected. For further information about 353 
the MS
E
 fragmentation spectrum and the proposed fragmentation pathway, consult 354 
Supplementary Information SI.3. 355 
 356 
Glucuronide conjugation of hydroxyindole metabolite (Metabolite 4) 357 
The second Phase II metabolite would correspond to a glucuronide conjugation of a 358 
non-detected Phase I metabolite, an indole-hydroxylated metabolite (m/z 439.20534, 359 
C21H31N2O8
+
, rt 1.72 min). The exact position of the hydroxyl group was not 360 
determined, but it was enclosed in the indole ring according to its fragmentation. 361 
Fragment at m/z 366.1159 (C17H20NO8
+
) corresponded to the well-known N-362 
isopropylmethylamine loss (73.0892 Da), indicating that the glucuronide, and thus the 363 
hydroxylation, was present in the indole ring. Another familiar fragment was at m/z 364 
86.0961 (C5H12N
+
), corresponding to the functionalised amine. Fragment at m/z 365 
190.0855 (C11H12NO2
+
) corresponded to the loss of the glucuronide conjugation of 366 
fragment at m/z 366. The other two fragments at m/z 175.0634 (C10H9NO2
+
) and m/z 367 
158.0592 (C10H8NO
+
) were also justified based on the proposed metabolite structure 368 
(Table 1). In supplementary information SI.4, the MS/MS fragmentation spectra of this 369 
metabolite and the proposed fragmentation pathway can be consulted. In this case, MS
E
 370 
fragmentation spectrum was not clean enough for observing the product ions of 371 
Metabolite 4, thus MS/MS experiments were carried out to better match the 372 
fragmentation observed to the metabolite structure. 373 
In order to enhance the confidence on the fragmentation observed in MS
E
, MS/MS 374 
spectra were also acquired for Metabolite 1, Metabolite 2 and Metabolite 3 (SI.5 to 375 
SI.8). 376 
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After the identification of the four metabolites previously described, a plausible 377 
metabolic pathway of the 5-MeO-MiPT was proposed (Figure 5).  378 
 379 
3.6. Implications of the obtained results 380 
A total of four 5-MeO-MiPT metabolites were elucidated in serum and urine: two Phase 381 
I and two Phase II metabolites. The two Phase I metabolites tentatively identified 382 
corresponded to the O-demethylated (Metabolite 1) and the N-oxide (Metabolite 2). Our 383 
study reveals that 5-MeO-MiPT is mostly metabolized as demethylation of the methoxy 384 
group in the indole ring. On the one hand, this tendency is similar to the one reported 385 
for the analogue 5-MeO-DiPT, where the demethylated metabolite was the most 386 
significant transformation product detected [30,32,33]. On the other hand, the N-387 
deisopropylated metabolite described for 5-MeO-DiPT has not been detected for 5-388 
MeO-MiPT, surely due to the change in the amine functionalisation. Moreover, the 389 
metabolite 2 detected in this work, corresponding to the oxidation in the amine moiety 390 
as N-oxide, has not been reported for 5-MeO-DiPT. Nevertheless, this 391 
biotransformation has been recently found for the tryptamine N,N-diallyltryptamine 392 
(DALT) [28,39]. The metabolism study of DALT derivatives revealed a vast number of 393 
biotransformations. However, in the case of 5-MeO-MiPT, only the formation of the 394 
amine oxidation as N-oxide has been found.  395 
Regarding Phase II metabolites, the glucuronide of the demethylated Phase I metabolite 396 
(Metabolite 3), and the glucuronide of the hydroxyindole metabolite (Metabolite 4), 397 
were detected. The no-detection of the hydroxyindole Phase I metabolite in the 398 
hydrolysed urine could indicate that the response of this metabolite was too low to be 399 
detected or that the corresponding glucuronide is not hydrolysed under the conditions 400 
used, as it has been observed for two biomarkers of testosterone consumption [40]. 401 
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In this study, a 5-MeO-MiPT dose of 0.27 mg/kg was injected to mice in order to 402 
elucidate metabolites and to study their pharmacokinetics in serum and urine. This dose, 403 
as explained previously, was based on a rough quantification of the 5-MeO-MiPT 404 
detected in the two pill samples, and a typical human consumer weighing 75 kg. 405 
However, metabolism studies of 5-MeO-DiPT [32] and DALT derivatives [28,39] in 406 
male Wistar rats referred much higher doses (10 mg/kg and 20 mg/kg, respectively) that 407 
used in this work. Surely, the use of higher doses facilitates the detection of higher 408 
number of metabolites, but it is possible that several of the identified metabolites at 409 
high-dose metabolism studies in rats cannot be found in human urine after consumption 410 
of a typical dose. In front of this dilemma, we preferred to use realistic doses, based on 411 
legal highs analyses or experiences described by consumers in order to obtain putative 412 
biological consumption markers, despite that some metabolites observed at higher dose 413 
can be ignored. On the basis of our results, Metabolite 1 and its glucuronide (Metabolite 414 
3), in addition to the parent compound, might be candidates as consumption markers, an 415 
issue that will be discussed in the next subsection. 416 
 417 
3.7. Prevalence and detectability of 5-MeO-MiPT metabolites in serum and urine 418 
The pharmacokinetic study of 5-MeO-MiPT revealed that most of the parent compound 419 
is demethylated and conjugated as glucuronide in the first 20 min, as shown in Figure 420 
6A. It should be remarked that experiences were performed in mice, which metabolism 421 
is faster than human. To have representative curves between percentage of each 422 
compound and excretion time, the response of each individual compound was related 423 
with the total response of all detected compounds by assuming that each compound 424 
gave the same response in the instrument. This approach was used due to the non-425 
availability of standards for the metabolites detected. This figure shows that in 426 
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bloodstream, the parent 5-MeO-MiPT has a drop of 75% in the first 30 min, while 427 
Metabolite 3 presents its maximum response at 20 min. For Metabolite 1 and Metabolite 428 
4, the response in bloodstream did not exceed 6% respect the initial 5-MeO-MiPT. At 429 
60 min, most of 5-MeO-MiPT was removed from bloodstream by urine excretion or 430 
metabolic pathways, while there was still around 30% of Metabolite 3. 431 
Regarding hydrolysed urine, Metabolite 1 presented the highest response, while 5-MeO-432 
MiPT only represented 38% respect to Metabolite 1 (Figure 3B). Metabolite 2 was 433 
minor (around 2%) and could not be detected at 3 hours. An important decrease 434 
between 3-4 hours was observed in the concentration of 5-MeO-MiPT and Metabolite 1. 435 
Nevertheless, after 6 hours, Metabolite 1 was still detected, at a concentration of 30 % 436 
respect to its concentration at 1 hour. As expected, Metabolite 3 and Metabolite 4 were 437 
not observed due to the enzymatic hydrolysis of glucuronides. In this way, Metabolite 1 438 
would be the most suitable biological consumption marker of 5-MeO-MiPT.  439 
In relation to the diluted raw urine (Figure 3C), the major compound found at 1 hour, in 440 
terms of response, was the parent 5-MeO-MiPT. Metabolite 3 represented around 80%, 441 
whereas Metabolite 1 was 50%. However, Metabolite 4 did not exceed the 2% of the 442 
response, being not detected at 4 hours. The elimination of 5-MeO-MiPT and its 443 
metabolites revealed that Metabolite 3 concentration remains constant for the first 2 444 
hours, while the 5-MeO-MiPT and Metabolite 1 show a decrease. Similarly to 445 
hydrolysed urine, the most important concentration fall was observed between 3 and 4 446 
hours. At 6 hours, the concentration of 5-MeO-MiPT represent around the 5% of its 447 
initial concentration, and Metabolite 3 the 10%. 448 
Once evaluated the pharmacokinetics of 5-MeO-MiPT, plausible consumption 449 
biomarkers can be proposed. The consumption of this tryptamine can be monitored in 450 
hydrolysed urine by the parent compound and the O-demethylated metabolite 451 
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(Metabolite 1). The detection of these biomarkers should be performed in hydrolysed 452 
urine, as the glucuronide cleavage of Metabolite 3 would increase the concentration of 453 
Metabolite 1. Both compounds were still detected after 24 hours of drug administration, 454 
as it can be seen in Figure 7, demonstrating that the proposed biomarkers reveal the 455 
consumption of 5-MeO-MiPT. Despite Metabolite 1 is the most abundant one in 456 
hydrolysed urine, it should not be used as 5-MeO-MiPT consumption marker 457 
individually. The detection of Metabolite 1 without the simultaneous detection of 5-458 
MeO-MiPT would generate a reasonable doubt about which is the tryptamine that have 459 
been consumed: 5-MeO-MiPT or the synthetic analogue of psilocin, 4-OH-MiPT. Thus, 460 
the presence of both 5-MeO-MiPT and Metabolite 1 after 24 hours in urine would 461 
reveal the consumption of this tryptamine. 462 
  463 
22 
 
4. Conclusions 464 
Due to the difficulties associated to the metabolism studies in humans, in this work the 465 
in vivo approach has been applied using adult male mice of the inbred strain C57BLJ/6 466 
as model. This has allowed the establishment of potential consumption markers of the 467 
synthetic tryptamine 5-MeO-MiPT. By the use of UHPLC-HRMS, two Phase I and two 468 
Phase II metabolites have been elucidated. The accurate-mass data acquired under MS
E
 469 
mode allowed the tentative identification of three metabolites, but elucidation of the 470 
fourth one required MS/MS experiments in order to obtain cleaner spectra. 471 
Nevertheless, all the metabolites were additionally confirmed by MS/MS experiments. 472 
After evaluating the results, the most important metabolite found was the O-473 
demethylated (Metabolite 1) and its glucuronide (Metabolite 3).  474 
The pharmacokinetic study revealed that 5-MeO-MiPT was rapidly metabolized, being 475 
almost completely removed in bloodstream after 60 min. In the case of urine samples, 476 
an important decrease of 5-MeO-MiPT and the two major metabolites was observed 477 
between 3 and 4 hours, although these three compounds were still detected after 6 478 
hours. The parent tryptamine 5-MeO-MiPT and the O-demethylated metabolite were 479 
both detected in hydrolysed urine collected 24 hours after administration. Both 480 
compounds are proposed as biological markers for monitoring 5-MeO-MiPT 481 
consumption in hydrolysed consumer’s urine, discarding the O-demethylated 482 
glucuronide because it would be transformed in Metabolite 1 after the hydrolysis step. 483 
The detection of the parent compound is crucial for differentiating the consumption of 484 
two chemically-related tryptamines, 5-MeO-MiPT and the psilocin analogue 4-OH-485 
MiPT. Data reported in this work will be useful for developing analytical methodologies 486 
for 5-MeO-MiPT consumption detection in hospitals and research centres.  487 
 488 
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